TCMD Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

Total Revenue: $75.3 million, a 23% increase year-over-year.
- Lymphedema Revenue: $62.2 million (up 23% YoY).
- Airway Clearance Revenue: $13.0 million (up 22% YoY).
Gross Margin: Increased by 250 basis points to 76.5%.
Adjusted EBITDA: $3.7 million, compared to an adjusted EBITDA loss of $0.3 million in the prior year.
Net Loss: Decreased to $1.8 million ($0.08 per diluted share) from $3.0 million ($0.13 per diluted share).
Cash Position: Approximately $75 million, down from $83.4 million at the end of 2025.

2. Strategic Updates and Business Highlights

Acquisition of Lymphotech: Minimal revenue contribution in Q1, but seen as a strategic move to enhance R&D capabilities and expand the product portfolio.
Operational Improvements: Successful implementation of AI technology for prior authorization processes, enhancing operational efficiency.
Sales Organization: Transitioning from capacity building to productivity, with improved territory productivity and CRM utilization.
Product Developments: FDA clearance for the next-generation AffloVest, expected to launch in time for the 2026-2027 winter respiratory season.

3. Forward Guidance and Outlook

2026 Revenue Guidance: Updated to $360 million to $368 million, reflecting confidence in commercial execution and the inclusion of Lymphotech.
Adjusted EBITDA Expectation: Projected between $49 million and $51 million for 2026.
Gross Margin Expectation: Anticipated to be between 76% and 77%.

4. Bad News, Challenges, or Points of Concern

Prior Authorization Changes: Introduction of new Medicare prior authorization requirements may create initial operational challenges and variability in approval rates across different MACs.
Operating Expenses: Increased by 19% YoY, reflecting ongoing investments in sales and marketing, R&D, and operational infrastructure.
Market Dynamics: Potential for variability in sales cadence due to the new prior authorization process, which may impact Q2 performance.

5. Notable Q&A Insights

Sales Dynamics: Management clarified that Q1 sales acceleration was not a pull-forward from Q2 but rather an effort to assist patients with orders before the prior authorization deadline.
Lymphotech Contribution: Expected to have minimal impact in the near term, with significant contributions anticipated from government grants supporting R&D efforts.
Market Awareness: The introduction of a new pharmaceutical for bronchiectasis is raising awareness but does not replace the need for airway clearance therapies.
Guidance Adjustments: Management is cautious about the impact of prior authorization on future sales and is monitoring MAC responses closely.

Overall, TCMD demonstrated strong financial performance in Q1 2026, with significant growth in both business lines, while also navigating potential challenges related to new regulatory requirements. The company remains optimistic about its strategic initiatives and long-term growth prospects.

TCMD — Tactile Systems Technology, Inc.